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Teratogenicity/Fetotoxicity
of DEHP in Mice
by 1. Tomita,* Y. Nakamura,* Y. Yagi* and K. Tutikawat
The embryonic/fetotoxic effects of DEHP on pregnant mice (ddY-Slc Y x CBA Cd) were
studied. DEHP was administered orally in dosages of0.05 ml/kg to 30.0 mg/kg on day 6, 7, 8, 9 or
10 of gestation. A single administration of DEHP over 0.1 ml/kg (1/300 of LD50) on day 7 of
gestation decreased the numbers and the body weight of living fetuses, whereas no significant
changes in the numbers ofliving fetuses (with no gross and skeletal abnormalities) were observed
compared with those of the control group, when 0.05 ml/kg (1/600 of LD50) of DEHP was
administered. The fetotoxicity (fetal death) was dose dependent. The LD50 and the nonfetolethal
maximum dosage of DEHP in its single, oral administration was 592 mg/kg and 64 mg/kg,
respectively. The latter value is much higher than an estimated DEHP intake from commercial
foodstuffs in men, which is approximately 0.03 mg/kg/day.
Introduction
Thedeleterious effects ofdi(2-ethylhexyl) phthalate
(DEHP) on developing embryos and/or fetuses in
animals have been reported by a number of
investigators (1-14).
The present reports are the summaries of our
studies (15, 16) carried out to determine the embryo
toxicity and fetotoxicity ofDEHP on ddY-Slc(SPF)
(9) x CBA(SPF)(d)mice. DEHP wasadministered
orally once during the period of pregnancy. The
dosages administered were from 1/30 to 1/1 ofLD50
(high-dose study) and from 1/600 to 1/30 of LD50
(low-dose study).
Through these studies, the nontoxic maximum
dose of DEHP in mice was determined, and steps
were taken to assess the risk of DEHP for human
reproduction.
Experimental
Virgin female mice of the ddY-Slc (SPF) strain
(Shizuoka Agricultural Cooperative Association for
Laboratory Animals), weighing 27-28 g (8-9 weeks
old), were housed with one male mouse of CBA
strain (National Institute of Genetics). The at-
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mosphere was maintained at 25 + 2°C and 50 + 5%
RH. Laboratory diet (Funahashi Farm Co.) and tap
water were provided ad libitum. DEHP (purity
over 99%) was obtained from Tokyo Kasei Co. Ltd.
MEHP was synthesized according to the method of
Kenyon (17) and was more than 99% pure as
determinedbyECD-GLCanalysis. Theexperimental
procedure is detailed in our previous paper (16).
Results
Figure 1 shows the body weight changes of
pregnant mice. The increase in body weight of the
mice was suppressed when 10 mi/kg of DEHP was
given PO once on day 7, 8, 9, or 10 ofgestation. The
suppression was especially clear when DEHP was
administered on day 7 or 8 ofgestation. A decrease
in the body weight of mice, however, was not
observed when a low dosage ofDEHP (0.05 ml and
0.1 ml/kg) wasgiven, evenon day 7ofgestation (see
inset in Fig. 1).
Table 1 summarizes the effects of DEHP on the
fetuses ofmice. The study consisted offour groups:
an untreated control group, two DEHP-treated
groups (high-nd low-dose groups) and an ethyl-
urethane-treatedgroup(positivecontrol). Asshown
inTable 1, thenumberofimplantationsperpregnant
mouse was not significantly different among the
controland DEHP-treatedgroups, butthenumbers
of embryos which suffered an early or late death
varied greatly, depending on the day and the72
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FIGURE 1. Effects ofdi(2-ethylhexyl) phthalate (DEHP) onthe
body weight changes ofpregnant mice. DEHP was given P0
in onedoseof10mi/kgon(0)the7th, (s)8th, (0)9th, or(A) 10th
day of gestation; (0) untreated control.
amount ofDEHP administered. A high incidence of
deadembryos wasfound inmicewhichhadreceived
DEHP on day 7 or 8 of gestation, whereas a low
incidence ofdead embryos was found in mice which
had received DEHP on days 6, 9, or 10. It must be
noted that a higher incidence of early and late
deaths among embryos occurred with the higher
and lower dosages of DEHP administration, res-
pectively. There was a high rate of gross and
skeletal abnormalities among the two groups of
mice which had received 2.5 or 7.5 ml ofDEHP/kg
on days 7 or 8 of gestation, respectively. No
abnormality was observed in the other two groups
ofmice receiving 0.05 or 0.1 ml DEHP/kg although
the average body weight of viable fetuses was
significantly lower (p < 0.01) than that of the
control group.
Thedetails ofthe grossandskeletalmalformation
in mouse fetuses due to DEHP administration are
shown in Table 2. Exencephaly, open eyelid, club
foot and bent or no tail were often found in the
malformed fetuses, while thoracic lumbar, sacral
andcaudalvertebraewereoftenfoundinanabnormal
shape. There was no case of a cleft palate.
Figure 2 shows the correlation between the
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death and abnormalities (gross and skeletal) of
fetuses versus the dosage of DEHP administered
on day 7 ofgestation. Froma straight line (y = 51.9
log x + 61.6, wherey = % offetaldeath, x = ml/kg
of DEHP administered) obtained with 5 log dosage
ofDEHP, the fetal LD50 was determined to be 592
mg/kg on assuming the specific gravity ofDEHP to
be 0.986. The dosage producing 2% offetal deaths,
i.e., the same mortality rate as found in the control
group, was about 64 mg/kg. The exact values ofthe
ineffective maximum dosage for gross and skeletal
abnormalities could not be determined because of
limited data, but these values are probably less
than 0.80 ml/kg (789 mg/kg) and 0.68 ml/kg (670
mg/kg), respectively, as judged from their dose-
response curve.
Our trial for the safety evaluation of DEHP with
respect to embryo/fetal toxicity is shown in Figure
3. As was demonstrated and stated above, the
maximum nonteratogenic (both gross and skeletal)
dose and median fetolethal dose (fetal LD50) in mice
are approximately the same, around 600 mg/kg,
while the maximum nonfetolethal dose in mice is
about 64 mg/kg. In humans, approximately 4 mg/kg
would be a possible maximum intake of DEHP by
blood transfusion or hemodialysis (18). The level
(unconditional) of the acceptable daily intake for
humans (ADI) is about 1 mg/kg/day (19).
The maximum intake of DEHP from foodstuffs
with which we are most concerned would not
exceed0.03mg/kg/day, assumingadailyfoodintake
as 1.5 kg/50 kg adult and an average content of
DEHP in our foodstuffs as 1 ppm (20).
A safety margin of approximately 21-fold thus
exists betweenthe nonfetolethal dose ofDEHP and
themaximum amount ofDEHP fromfoodstuffs, ifa
100-fold margin is simply set to extrapolate the
data from mice to humans.
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FIGURE 2. Fetotoxicity of DEHP in mice: (o) fetal death; (A)
gross abnormalities; (O) skeletal abnormalities.TERATOGENICITY/FETOTOXICITY OF DEHP IN MICE
Table 1. Effects of DEHP on mouse fetuses.
Number of Number ofdead embryos Number of Numbers of
implanta- (% live fetuses) living abnormalitiesd
Dose ad- tions (no. embryos Average
Day of ministered, pregnant Early Late (% live body weight
Group gestation ml/kgab mice) death death fetuses)c Gross Skeletal offetuses, g
(High dose)
untreated - - 56(5) 0 0 56(100) 0 0 1.41 ± 0.06
control
DEHP 6 2.5(1/12) 60(6) 1( 1.7) 7(11.7) 52(86.7) 1( 1.9) 3( 5.8) 1.31 ± 0.12e
(high dose) 7 1.0(1/30) 54(6) 13(24.1) 19(35.2) 22(40.7) 3(13.6) 4(18.2) 1.20 ± 0.09e
2.5(1/12) 36(5) 21(58.3) 10(27.8) 5(13.9) 4(80.0) 3(60.0) 1.17 ± 0.18e
5.0(1/6) 43(4) 27(62.8) 16(37.2) 0
10.0(1/3) 59(5) 44(74.6) 15(25.4) 0
8 7.5(1/4) 66(6) 8(12.1) 29(43.9) 29(43.9) 19(65.5) 24(82.8) 1.07 ± 0.07e
10.0(1/3) 83(8) 15(18.1) 53(63.9) 15(18.1) 7(46.7) 5(33.3) 1.23 ± 0.14e
9 7.5(1/4) 30(3) 2( 6.7) 1( 3.3) 27(90.0) 1( 3.7) 0 1.28 ± 0.08e
10.0(1/3) 48(5) 2( 4.2) 2( 4.2) 44(91.7) 9(20.5) 0 1.32 ± 0.09e
30.0(1/1) 48(5) 2( 4.2) 16(33.3) 30(62.5) 9(30.0) 5(16.7) 1.08 ± 0.12e
10 10.0(1/3) 65(7) 2( 3.1) 1( 1.5) 62(95.4) 0 0 1.37 ± 0.13'
30.0(1/1) 63(7) 3( 4.8) 3( 4.8) 57(90.5) 4( 6.5) 0 1.28 ± 0.16e
(Low dose)
untreated - - 301(31) 2( 0.7) 4( 1.3) 259(98.0) 0 0 1.39 ± 0.06
control
DEHP 7 0.05(1/600) 200(22) 0 5( 2.5) 195(97.5) 0 0 1.31 ± 0.lle
(low dose) 0.1(1/300) 98(11) 2( 2.0) 9( 9.2) 87(88.8) 0 0 1.27 ± 0.13e
1.0(1/30) 94(10) 1( 1.1) 55(58.5) 38(40.4) 3( 7.9) 7(18.4) 1.22 ± 0.lOe
Ethyl- 7 1.5 34(4) 1( 2.9) 5(14.7) 28(82.4) 4(14.3) 4(14.3) 1.08 ± 0.22
urethane 8 1.5 44(5) 3( 6.8) 0 41(93.2) 1( 2.4) 1( 2.4) 1.20 ± 0.10
(IP) 9 1.5 41(4) 1( 2.4) 25(61.0) 15(36.6) 13(86.7) 15(100) 0.85 ± 0.12
10 1.5 22(3) 0 0 22(100) 20(90.9) 22(100) 0.87 ± 0.06
aOral administration.
bNumbers in parentheses denote fraction of acute LD50 (30 ml/kg).
cNumbers in parentheses indicate percent oflive fetuses based on total number ofimplantations.
dNumbers in parentheses indicate percent abnormalities based on total numbers of live fetuses.
eSignificantly different from untreated control at 99% level (p < 0.01).
fSignificantly different from untreated control at 95% level (p < 0.05).
Table 2. Incidence of gross and skeletal malfonnations in the fetus of mouse after di(2-ethylhexyl) phthalate (DEHP)
administration at various days of gestation.
Day6 Day 7 Day8 Day9 Day 10
Untreated 2.5 1.0 2.5 7.5 10.0 7.5 10.0 30.0 10.0 30.0
control (ml/kg) (ml/kg) ml/kg (ml/kg) ml/kg (mi/kg) ml/kg (ml/kg) mi/kg (ml/kg)
No. fetuses examined 56 60 54 36 66 83 30 48 48 63 65
No. live fetuses (56) (52) (22) (5) (29) (15) (27) (44) (30) (62) (57)
No. gross abnormalities 0 1 3 4 19 7 1 9 9 0 4
MI,a (1.9) (13.6) (80.0) (65.5) (46.7) (3.7) (20.5) (30.0) (6.5)
Exencephaly 0 0 1 0 7 2 0 0 0 0 0
Open eyelid 0 0 1 0 5 7 0 8 3 0 0
Abdominal hernia 0 0 0 0 1 0 0 0 0 0 0
Club foot 0 0 1 1 5 3 1 1 2 0 0
Poly-dactylia 0 0 0 0 1 0 0 0 0 0 1
Bent tail or none 0 1 1 4 5 4 0 0 0 0 5
Subcutaneous bleeding 0 0 0 0 0 0 0 0 4 0 0
No. skeletal abnormalities 0 3 4 3 24 5 0 0 5 0 0
M%)a (5.8) (18.2) (60.0) (82.8) (33.3) (16.7)
Skull vertebrae 0 0 1 0 7 2 0 0 0 0 0
Cervical vertebrae 0 2 0 0 0 0 0 0 0 0 0
Thoracic vertebrae 0 2 4 2 21 5 0 0 1 0 0
Lumbar vertebrae 0 0 1 3 8 4 0 0 3 0 0
Sacralvertebrae 0 0 1 1 6 4 0 0 1 0 0
Caudal vertebrae 0 1 1 5 3 0 0 0 0 0 0
Ribs 0 1 4 2 20 5 0 0 0 0 0
aPercent gross or skeletal malformations based on total number of live fetuses examined.
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FIGURE 3. Safety evaluation of DEHP in respect to fetotoxicity.
Discussion
Consistent results have not always been obtained
in the reproductive/fetotoxic studies ofDEHP, due
mainly to differences in the dosage of DEHP, the
duration and the route of administration. The
animal species employed in the experiments is
another crucial factor in determining the toxic
effects. The effects of DEHP on reproductive
function or fetal toxicity in several animal species
have been performed by several investigators and
are well reviewed (9, 12). The toxic effects of
DEHP on the mouse fetuses which have been
demonstrated in recent examinations (7, 15, 16)
should be added. It must be also added that the
metabolic fate of DEHP in mice seems to be
somewhat similar to that in man when solely the
metabolic formation of MEHP is considered (21).
As MEHP is known to be aprincipal-and possibly
the active-metabolite of DEHP (12, 16, 22), the
similarity between mice and humans may have
some advantage in extrapolating the mouse data to
men.
AsshowninFigure3, thenonfetolethalmaximum
doseofDEHPinmicebyasingle oraladministration
is estimated to be about 64 mg/kg. This value is
approximately 2100 timesthat (0.03mg/kg) whichis
aconceivable levelofDEHPintake fromcommercial
foodstuffs. Judging exclusively from the above
experimental results and estimation, it seems to be
unlikely that DEHP will produce any immediate
threattohumanreproduction, thoughtheconclusive
assessment of DEHP should await further study.
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